Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Midostaurin companion diagnostic - Invivoscribe/Novartis Oncology

Drug Profile

Midostaurin companion diagnostic - Invivoscribe/Novartis Oncology

Alternative Names: FLT3 companion diagnostic; LeukoStratCDx FLT3 Mutation Assay; PKC 412 companion diagnostic - Invivoscribe/Novartis

Latest Information Update: 03 Dec 2018

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Takara Bio
  • Developer Invivoscribe Technologies; Novartis Oncology
  • Class Diagnostic agents
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Acute myeloid leukaemia

Most Recent Events

  • 29 Nov 2018 Launched for Acute myeloid leukaemia (Diagnosis) in European Union (unspecified route) before November 2018
  • 29 Nov 2018 Registered for Acute myeloid leukaemia (Diagnosis) in European Union, Norway, Iceland, Liechtenstein (unspecified route) before November 2018
  • 29 Nov 2018 Invivoscribe announces intention to launch to gilteritinib companion diagnostic in the US for Acute myeloid leukaemia

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top